Glioblastomas are malignant grade 4 brain tumors, and they can be difficult to treat, according to the American Brain Tumor Association. Each year, more than 12,000 glioblastomas are diagnosed in the U.S., accounting for 14% of all primary brain tumors.
Three patients were given an experimental CARv3-TEAM-E T-cell medicine that works to target the epidermal growth factor receptor variant III and a wild-type EGFR protein.
“Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants,” the researchers said.
The 72-year-old patient’s tumor shrunk by 18.5% in two days. The research logged five months, and no adverse events greater than grade 3 or dose-limiting toxic effects were reported.
The findings were published March 13 in The New England Journal of Medicine. On the same day, a separate published study using a CAR-T therapy among six patients with advanced glioblastoma also found diminished tumors. Neither study’s results can be deemed a response, but the early research hints at safety and efficacy potential.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
